immun
antibodi
phagedisplay
librari
construct
b
cell
sar
convalesc
patient
clone
select
librari
use
whole
inactiv
sarscov
virion
target
one
human
scfv
character
extens
recogn
sar
pseudoviru
vivo
compet
sar
sera
bind
sarscov
high
affin
equilibrium
dissoci
constant
k
nm
also
potent
neutral
activ
infect
pseudoviru
express
sarscov
protein
vitro
final
found
recogn
epitop
protein
especi
within
amino
acid
protein
studi
first
made
human
neutral
antibodi
recogn
epitop
protein
like
natur
antibodi
sera
also
may
help
us
better
understand
immunolog
characterist
sar
protein
sar
vaccin
design
human
sarscov
neutral
antibodi
epitop
protein
worldwid
outbreak
sever
acut
respiratori
syndrom
sar
newli
emerg
diseas
caus
sarsassoci
coronaviru
sarscov
repres
recent
threat
human
health
sarscov
highli
contagi
clinic
cours
sever
high
mortal
outbreak
effect
agent
avail
sar
prophylaxi
therapi
although
passiv
serotherapi
use
polyclon
immun
sera
convalesc
sar
patient
shown
effici
treatment
sar
potenti
provid
immedi
protect
infect
human
sera
limit
suffici
amount
possibl
contamin
infecti
agent
therefor
viabl
strategi
sar
prophylaxi
treatment
produc
human
antibodi
engin
technolog
viral
envelop
protein
initi
entri
virus
host
cell
bind
cell
surfac
receptor
follow
conform
chang
lead
membran
fusion
shown
spike
protein
sarscov
respons
bind
receptor
angiotensinconvert
enzym
initi
entri
host
cell
also
identifi
domin
antigen
determin
elicit
neutral
antibodi
infect
sarscov
sever
data
demonstr
antibodi
select
use
protein
antigen
semisynthet
antibodi
librari
memori
repertoir
potent
neutral
activ
sarscov
infect
present
studi
gener
sarscov
immun
antibodi
librari
isol
singl
chain
fv
scfv
high
specif
affin
select
use
whole
sarscov
virion
rather
singl
recombin
protein
antigen
result
show
select
scfv
neutral
activ
recogn
epitop
protein
especi
within
amino
acid
protein
studi
would
aid
make
neutral
antibodi
recogn
epitop
protein
like
natur
antibodi
sera
better
understand
immunolog
characterist
sar
protein
design
sar
vaccin
cell
plasmid
antibodi
vero
suppli
institut
microbiolog
epidemiolog
beij
china
vector
purchas
novagen
darmstadt
germani
phagemid
provid
dr
andrew
bradburi
lo
alamo
nation
laboratori
vector
provid
dr
hyeryun
choe
harvard
medic
school
antibodi
use
horseradish
peroxidas
hrp
conjug
amersham
pharmacia
england
hrpconjug
antihuman
fc
fitcconjug
antimous
igg
sigma
st
loui
mo
usa
hrpconjug
antimous
igg
pierc
rockford
il
usa
antihistag
novagen
darmstadt
germani
virion
prepar
sarscov
inactiv
biosafeti
level
laboratori
purifi
differenti
centrifug
previous
describ
construct
scfv
librari
total
rna
prepar
peripher
blood
lymphocyt
four
convalesc
sar
patient
follow
cdna
synthesi
v
h
heavi
chain
variabl
region
v
l
gene
light
chain
variabl
region
amplifi
use
primer
list
tabl
clone
phagedisplay
vector
recombin
transform
escherichia
coli
electropor
transform
plate
dish
yt
contain
glucos
lgml
ampicillin
lgml
tetracyclin
coloni
collect
scrape
rescu
helper
phage
final
store
primari
scfv
librari
divers
assess
scfv
librari
number
individu
coloni
primari
librari
randomli
pick
phagemid
scfv
prepar
describ
previous
amplifi
polymeras
chain
reaction
pcr
individu
scfv
gene
digest
bstni
fingerprint
coloni
analyz
agaros
gel
select
phage
scfv
sarscov
immunotub
coat
purifi
sarscov
virion
na
co
ph
block
h
bsa
phosphatebuff
salin
pb
incub
h
room
temperatur
phage
scfv
ml
pb
contain
bovin
serum
albumin
bsa
triton
intens
wash
pbst
tween
pb
bound
phage
antibodi
elut
glycinehcl
ph
immedi
neutral
triscl
ph
elut
phage
scfv
subject
next
round
infect
rescu
select
five
round
pan
higher
binder
sarscov
select
enzymelink
immunosorb
assay
elisa
elisa
ninetysixwel
microtit
plate
nunc
rochest
ny
coat
overnight
inactiv
sarscov
particl
na
co
ph
block
bsa
pb
incub
individu
phage
scfv
pb
contain
bsa
five
wash
pbst
bound
antibodi
detect
hrpconjug
antibodi
follow
incub
orthophenylenediamin
opd
substrat
color
reaction
measur
nm
biorad
elisa
reader
hercul
ca
usa
express
purif
scfv
order
obtain
larg
amount
scfv
gene
select
phage
scfv
clone
human
v
k
primer
sali
j
k
sali
gaagttatggtcgaccctccggaacctaggacggtsascttggtccc
note
set
human
antibodi
primer
amplif
v
h
v
l
gene
b
cell
sra
patient
optim
base
previou
public
ital
indic
flank
sequenc
primer
underlin
indic
restrict
enzym
site
bold
indic
primer
sequenc
amplifi
gene
human
v
h
v
l
vector
express
e
coli
scfv
inclus
bodi
denatur
urea
purifi
gel
filtrat
column
sephacryl
hr
mm
previous
describ
sdspage
western
blot
protein
sampl
separ
electrophoresi
sdspage
transfer
onto
membran
membran
block
nonfat
milk
pb
incub
mous
antihistag
antibodi
follow
hrpconjug
antimous
igg
specif
protein
band
visual
autoradiographi
kodak
xray
film
competit
inhibit
assay
sera
convalesc
sar
patient
time
dilut
pb
incub
h
serial
twofold
dilut
purifi
scfv
start
concentr
lgml
mixtur
sera
dilut
scfv
subject
plate
coat
sarscov
particl
incub
anoth
h
hrpconjug
antihuman
fc
ad
secondari
antibodi
follow
procedur
describ
elisa
antibodi
affin
assay
bind
kinet
scfv
sarscov
analyz
use
variabl
angl
spectroscop
ellipsomet
berifli
sarscov
virion
coval
immobil
protein
chip
scfv
solut
ad
chip
surfac
bind
kinet
paramet
evalu
antibodi
realtim
bind
curv
prepar
lucsar
pseudoviru
lucsar
pseudoviru
system
prepar
base
method
describ
briefli
mammalian
cell
cotransfect
use
three
vector
mammalian
express
vector
pmt
code
sarscov
protein
pcmvr
code
mulv
gag
pol
phr
luc
code
luciferas
h
postinfect
lucsar
pseudovirus
packag
virion
infect
cell
collect
cultur
supernat
vitro
neutral
assay
lucsar
pseudoviru
system
use
infect
model
evalu
neutral
activ
scfv
first
lucsar
pseudovirus
preincub
serial
twofold
dilut
purifi
scfv
start
concentr
lgml
vero
cell
infect
lucsar
pseudoviru
without
scfv
h
incub
cultur
medium
refresh
dmem
contain
fb
continu
cultur
anoth
h
infect
vero
cell
lyse
assay
use
luminomet
dl
readi
model
tartu
estonia
measur
luciferas
activ
infect
cell
immunofluoresc
assay
vero
cell
monolay
infect
lucsar
pseudoviru
fix
mixtur
aceton
methanol
block
goat
sera
slide
incub
purifi
scfv
mous
antihistag
final
fitclabel
antimous
igg
scfv
bound
sar
pseudoviru
vero
cell
visual
fluoresc
microscop
sar
antigen
protein
prepar
sar
protein
express
human
fc
igg
cho
cell
briefli
ectodomain
amino
acid
protein
human
fc
igg
clone
pmt
stabli
express
cell
line
select
transfect
cho
cell
h
cultur
cultur
medium
recov
incub
protein
asepharos
bead
h
bead
wash
three
time
pb
bound
protein
elut
sdspage
sampl
load
buffer
min
protein
separ
sdspage
identifi
western
blot
use
hrpgoat
antihuman
fc
antibodi
visual
autoradiographi
x
film
vector
encod
fusion
protein
residu
human
fc
igg
transfect
cell
h
protein
produc
transfect
cell
cultur
supernat
subject
sdspage
western
blot
analysi
code
sequenc
residu
protein
pcramplifi
fulllength
gene
stop
codon
also
insert
protein
sequenc
pcr
clone
express
vector
restrict
enzym
site
ncoi
ecori
identif
sequenc
protein
express
induc
iptg
e
coli
protein
sampl
analyz
use
sdspage
transform
nitrocellulos
membran
blot
scfv
order
make
larg
divers
scfv
librari
high
affin
sarscov
use
phagedisplay
vector
four
sar
lymphocyt
repertoir
antibodi
sera
show
high
titer
bind
sarscov
use
pcr
techniqu
four
group
v
h
seven
group
v
l
four
v
j
three
v
k
amplifi
fig
set
human
antibodi
primer
tabl
optim
base
previou
public
amplifi
v
l
v
h
respect
insert
vector
electropor
transform
e
coli
make
primari
scfv
librari
assess
divers
scfv
librari
coloni
randomli
select
scfv
gene
di
fig
construct
sar
immun
scfv
librari
four
group
v
h
seven
group
v
l
four
v
j
three
v
k
amplifi
rtpcr
total
rna
prepar
peripher
blood
lymphocyt
four
convalesc
sar
patient
follow
cdna
synthesi
v
h
v
l
gene
amplifi
use
primer
list
tabl
b
scfv
clone
randomli
select
primari
librari
gene
amplifi
pcr
c
fingerprint
scfv
gene
digest
h
bstni
analyz
agaros
gel
show
divers
primari
antibodi
librari
five
pan
round
show
enrich
scfvphage
sarscov
purifi
sar
viral
particl
antigen
five
round
select
perform
accord
standard
procedur
signific
chang
immobil
control
bsa
last
three
round
gest
bstni
sinc
number
bstni
site
randomli
exist
variabl
region
antibodi
shown
fig
clone
contain
similar
size
fulllength
scfv
around
bp
howev
scfv
clone
show
uniqu
bstnidigest
fingerprint
pattern
fig
indic
individu
clone
primari
librari
differ
librari
calcul
divers
member
biopan
perform
stringent
condit
enrich
phage
scfv
sarscov
phage
scfv
pfu
input
subject
immunotub
coat
sarscov
virion
h
incub
immunotub
intens
wash
remov
nonspecif
binder
bound
phage
output
calcul
pan
ratio
outputinput
gradual
increas
third
fourth
round
dramat
increas
fifth
round
howev
phage
scfv
immobil
control
bsa
show
signific
chang
fig
result
indic
phage
scfv
sarscov
specif
enrich
five
round
pan
fifth
pan
round
phage
clone
randomli
select
elisa
evalu
bind
activ
sarscov
identifi
clone
specif
bind
sarscov
one
refer
specif
binder
consist
highest
affin
identifi
v
famili
v
famili
base
deduc
amino
acid
sequenc
fig
clone
express
inclus
bodi
e
coli
refold
scfv
done
gel
filtrat
column
sephacryl
puriti
analyz
singl
band
kda
use
sdspage
fig
singl
band
specif
blot
antihistag
antibodi
fig
indic
scfv
histag
test
whether
solubl
scfv
maintain
specif
bind
activ
sarscov
perform
competit
assay
clearli
shown
significantli
decreas
bind
sar
convalesc
sera
sarscov
inhibit
get
stronger
increas
amount
scfv
wherea
control
scfv
affect
sera
activ
fig
data
suggest
bear
similar
antigen
epitop
natur
antibodi
sar
convalesc
sera
bind
kinet
scfv
sarscov
analyz
use
variabl
angl
spectroscop
ellipsomet
equilibrium
dissoci
constant
scfv
evalu
k
nm
tabl
antibodi
realtim
bind
curv
lucsar
pseudoviru
proven
effici
vitro
model
studi
sarscov
infec
fig
amino
acid
sequenc
scfv
deduc
dna
sequenc
framework
region
complementar
determin
region
v
h
v
l
shown
determin
vbase
sequenc
directori
base
sequenc
scfv
identifi
v
famili
v
famili
tion
model
luciferas
activ
reflect
infect
replic
pseudoviru
host
cell
use
lucsar
pseudoviru
system
test
neutral
activ
scfv
use
luminomet
result
shown
fig
significantli
inhibit
infect
sar
pseudoviru
vero
cell
inhibit
effect
dosedepend
manner
wherea
control
scfv
caus
effect
condit
next
determin
whether
recogn
protein
assembl
sar
pseudoviru
vivo
vero
cell
first
infect
lucsar
pseudoviru
subject
immunofluoresc
assay
shown
fig
scfv
rather
scfv
neg
control
recogn
sar
pseudoviru
infect
vero
cell
fig
b
mockinfect
cell
fig
result
consist
convalesc
sera
posit
control
data
shown
indic
scfv
could
bind
protein
assembl
viral
particl
vivo
order
identifi
bind
epitop
test
bind
activ
scfv
sfc
protein
use
western
blot
analysi
shown
fig
b
purifi
scfv
recogn
whole
protein
bind
protein
narrow
epitop
scfv
construct
express
recombin
protein
fragment
use
western
blot
analysi
found
tabl
kinet
rate
bind
affin
purifi
scfv
recogn
protein
bind
fig
result
suggest
epitop
scfv
may
within
amino
acid
protein
confirm
made
fragment
found
scfv
recogn
fragment
fig
data
strongli
demonstr
epitop
scfv
locat
protein
especi
within
amino
acid
protein
antibodi
use
centuri
prevent
treatment
infecti
diseas
viral
diseas
antibodi
block
viral
entri
uninfect
cell
promot
antibodydirect
cellmedi
cytotox
natur
killer
cell
neutral
viru
alon
particip
complement
shown
protein
dimer
trimer
locat
surfac
sar
virion
import
bind
receptor
molecul
initi
entri
host
cell
order
obtain
neutral
antibodi
mimic
natur
antibodi
elicit
viral
pathogen
construct
immun
scfv
librari
deriv
b
cell
four
sar
patient
high
titer
sar
virion
b
cell
repertoir
contain
variou
antibodi
high
specif
matur
affin
sarscov
compar
synthet
antibodi
librari
immun
librari
like
obtain
naturelik
antibodi
high
specif
affin
anoth
featur
obtain
naturelik
antibodi
use
complet
sarscov
virion
rather
singl
recombin
protein
antigen
select
reason
viral
particl
antigen
bear
natur
intact
conform
immunogen
determin
thu
feasibl
select
neutral
antibodi
pan
whole
sarscov
virion
rather
singl
recombin
protein
select
scfv
high
affin
show
specif
bind
sarscov
particl
vitro
sar
pseudoviru
vivo
moreov
epitop
recogn
scfv
suspect
fragment
accord
previou
work
protein
especi
within
amino
acid
protein
consist
recent
publish
work
rabbit
competit
assay
show
abl
abrog
bind
sar
immun
sera
sarscov
suggest
bear
similar
antigen
epitop
nativ
sar
antibodi
sera
neutral
abil
may
effect
via
block
epitop
sar
virion
protein
protein
verifi
import
epitop
elicit
neutral
antibodi
previou
studi
sarscov
coronavirus
howev
neutral
human
antibodi
protein
sarscov
report
could
signific
develop
cocktail
human
sarscov
neutral
monoclon
antibodi
sar
prophylaxi
treatment
summari
describ
effect
method
obtain
antibodi
mimic
natur
antibodi
immun
sera
use
sar
virion
rather
singl
recombin
protein
antigen
select
immun
antibodi
librari
studi
would
signific
develop
neutral
antibodi
also
better
understand
immunogen
characterist
sar
protein
design
sar
vaccin
fig
epitop
map
scfv
western
blot
analysi
scfv
recogn
fc
protein
bind
fc
protein
b
protein
fc
fc
recogn
antihuman
fc
antibodi
control
c
sdspage
analyz
express
protein
fragment
western
blot
show
bind
scfv
recogn
